Minor Splicing Factor RNPC3 Is Essential for the Germinal Center B Cell Response
European Journal of Immunology · 2025
DOI: 10.1002/eji.202451508 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Immunology, 2025. Verfasst von Jing Wang und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology and Microbiology, School of Life Sciences, Southern University of Science and Technology, Shenzhen, China. Hauptthemen laut MEDLINE: Germinal Center, B-Lymphocytes, RNA-Binding Proteins. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 67 Literaturangaben. Gefördert von: National Key R&D Program of China, Shenzhen Science and Technology Innovation Committee, National Natural Science Foundation of China.
Abstract (Originalsprache)
Germinal center (GC) response ensures the generation of diverse and high‐affinity antibodies during the T cell‐dependent (TD) immune response. This process is controlled by coordinated transcriptional and posttranscriptional gene regulatory mechanisms. Minor intron splicing is known to be involved in posttranscriptional regulation of gene expression. RNA‐binding region (RNP1, RRM) containing 3 (RNPC3) is a minor spliceosome component involved in stabilizing the U11/U12 di‐snRNP complex, which is essential for minor intron splicing. However, it remains unclear if RNPC3 and RNPC3‐related gene regulatory mechanisms are important for the TD immune response. In this study, we conditionally ablated RNPC3 in activated B cells and showed that the mutant mice had defective antibody generation due to impaired GC B cell response. We demonstrate that RNPC3 deficiency inhibits the proliferation and promotes the apoptosis of activated B cells. Mechanistically, we show that RNPC3 regulates the development of GC B cells in a minor spliceosome‐dependent manner by controlling the removal of minor introns from minor intron‐containing genes associated with cell proliferation and apoptosis. Our study thus uncovers a previously unappreciated role for RNPC3 in regulating GC B cell response.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Immunology and Microbiology, School of Life Sciences, Southern University of Science and Technology, Shenzhen, China.
- Department of Basic Medicine, School of Medicine, Taizhou University, Taizhou, China.
- School of Biological and Pharmaceutical Engineering, Lanzhou Jiaotong University, Lanzhou, China.
- Jiangxi Province Key Laboratory of Traditional Chinese Medicine Pharmacology, Institute of Traditional Chinese Medicine Health Industry, China Academy of Chinese Medical Sciences, Nanchang, China.
- Jiangxi Health Industry Institute of Traditional Chinese Medicine, Nanchang, China.
- School of Medicine, Chengdu Women's and Children's Central Hospital, University of Electronic Science and Technology of China, Chengdu, China.
ORCID-Profile: Jing Wang, Shengli Xu, Xijun Ou
Förderung
- National Key R&D Program of China
- Shenzhen Science and Technology Innovation Committee
- National Natural Science Foundation of China
- National Key Research and Development Program of China
Zitieren
APA
Wang, J., Ruan, G. X., Li, Y., Xiao, X., Zhu, Z., Chen, W., Huang, H., Zhang, R., Wang, R., Chen, M., Guo, L., Li, Y., Xu, S., & Ou, X. (2025). Minor Splicing Factor RNPC3 Is Essential for the Germinal Center B Cell Response. European Journal of Immunology. https://doi.org/10.1002/eji.202451508
Vancouver
Wang J, Ruan GX, Li Y, Xiao X, Zhu Z, Chen W, et al. Minor Splicing Factor RNPC3 Is Essential for the Germinal Center B Cell Response. European Journal of Immunology. 2025. doi:10.1002/eji.202451508
BibTeX
@article{Wang2025,
author = {Wang, Jing and Ruan, Gui-Xin and Li, Yuxing and Xiao, Xiong and Zhu, Zhijian and Chen, Wenjing and Huang, Hengjun and Zhang, Rui and Wang, Ruisi and Chen, Meiyuan and Guo, Ling and Li, Yan and Xu, Shengli and Ou, Xijun},
title = {Minor Splicing Factor RNPC3 Is Essential for the Germinal Center B Cell Response},
journal = {European Journal of Immunology},
year = {2025},
doi = {10.1002/eji.202451508}
}
EUVIMED